Citi lowered the firm’s price target on Danaher to $290 from $280 and keeps a Buy rating on the shares post the Q1 report. While instruments remained more muted in the quarter, the higher end products for academic customers held in well, the analyst tells investors in a research note. The firm cites visibility into the recovery and higher estimates for the target increase.